netFormulary Joint Medicines Formulary NHS
Airedale NHS Foundation Trust
Airedale, Wharfedale and Craven CCG
 
 Search
 Formulary Chapter 8: Malignant disease and immunosuppression - Full Chapter
Notes:
Unless explicitly stated, any brand names included in brackets next to a drug's generic name are there solely to aid searching and identification, and should not be considered to limit use to that specific brand.  
Chapter Links...
 Details...
08.02.03  Expand sub section  Rituximab and alemtuzumab
Cytotoxic Drug Obinutuzumab (Gazyvaro®)
View adult BNF View SPC online View childrens BNF  Track Changes
Restricted Drug Restricted
Red
NHS England
BlueTeq
  • Obinutuzumab Infusion (Gazyvaro®)

Consultant Haematologist use only

Blueteq® registration and approval for use is required for this product before it may be dispensed.

 
Link  NICE TA343: Obinutuzumab in combination with chlorambucil for untreated chronic lymphocytic leukaemia (June 2015)
Link  NICE TA472: Obinutuzumab with bendamustine for treating follicular lymphoma refractory to rituximab (August 2017)
Link  NICE TA513: Obinutuzumab for untreated advanced follicular lymphoma (March 2018)
Link  NICE TA629: Obinutuzumab with bendamustine for treating follicular lymphoma after rituximab (May 2020)
 
Cytotoxic Drug Ofatumumab  (Arzerra®)
View adult BNF View SPC online View childrens BNF  Track Changes
Restricted Drug Restricted
Red
  • Ofatumumab Infusion (Arzerra®) 
     
 
Link  NICE TA344: Ofatumumab in combination with chlorambucil or bendamustine for untreated chronic lymphocytic leukaemia (June 2015)
 
Cytotoxic Drug Rituximab (MabThera® Truxima®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
  • Rituximab Infusion
  • Rituximab Subcutaneous Injection
 
Link  NICE TA137: Rituximab for the treatment of relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma (February 2008)
Link  NICE TA174: Rituximab for the first-line treatment of chronic lymphocytic leukaemia (July 2009)
Link  NICE TA193: Rituximab for the treatment of relapsed or refractory chronic lymphocytic leukaemia (July 2010)
Link  NICE TA243: Rituximab for the first-line treatment of stage III-IV follicular lymphoma (January 2012)
Link  NICE TA65 Rituximab for agressive non-Hodgkins lymphoma (September 2003)
Link  TA308: Rituximab in combination with glucocorticoids for treating anti-neutrophil cytoplasmic antibody-associated vasculitis (March 2014)
 
 ....
Key
note Notes
Section Title Section Title (top level)
Section Title Section Title (sub level)
First Choice Item First Choice item
Non Formulary Item Non Formulary section
Restricted Drug
Restricted Drug
Unlicensed Drug
Unlicensed
Track Changes
Display tracking information
click to search medicines.org.uk
Link to adult BNF
click to search medicines.org.uk
Link to children's BNF
click to search medicines.org.uk
Link to SPCs
Cytotoxic Drug
Cytotoxic Drug
CD
Controlled Drug
High Cost Medicine
High Cost Medicine
Cancer Drugs Fund
Cancer Drugs Fund
NHSE
NHS England
Homecare
Homecare
CCG
CCG

Traffic Light Status Information

Status Description

Green

Green - Drugs suitable for generalised use in accordance with position summary. Inform primary care of need to prescribe using a TTO chart if in patient or Treatment Advice Note (TAN) if Outpatient.   

Amber

Amber - these drugs require specialist initiation or recommendation  

Amber SCG

Amber Share Care - Drugs suitable for generalist use, in accordance with position summary, normally following specialist initiation and stabilisation. Ongoing division of responsibility for drug and disease monitoring between specialist and GP by a Shared Care Guideline (SCG). If no SCG in place status reverts to red.  

Red

Red - Drugs for specialist use only, in accordance with position summary. GP’s should not be asked to prescribe these products.  

Red ULM

Red ULM - Unlicensed medicines for specialist use only, in accordance with position summary. GP’s should not be asked to prescribe these products.  

Grey

Grey drugs - No formal commissioning position. Check appropriate CCG /NHSE commissioning list or contact CCG/NHSE Medicines Management team for advice. Fill in individual funding request for appropriate CCG/NHSE. This will need to be signed by the Chief Pharmacist and a copy of the relevant DTC submission attached.   

Black

Black - Drugs not routinely commissioned so should not usually be prescribed  

netFormulary